Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22564678 | 0.98 | PAOX (0.53) | SIGMAR1PAOXALOX15KEAP1SMN1; SMN2 | |
| SCHEMBL31092072 | 0.98 | PAOX (0.53) | SIGMAR1PAOXALOX15KEAP1SMN1; SMN2 | |
| SCHEMBL26488666 | 0.98 | PAOX (0.53) | SIGMAR1PAOXALOX15KEAP1SMN1; SMN2 | |
| SCHEMBL3970460 | 0.98 | PAOX (0.53) | SIGMAR1PAOXALOX15KEAP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27751183 | 0.98 | SIGMAR1 (0.48) | SIGMAR1PAOXALOX15KEAP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3677133 | 0.98 | SIGMAR1 (0.48) | SIGMAR1PAOXALOX15KEAP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL20507343 | 0.95 | PAOX (0.52) | SIGMAR1PAOXALOX15KEAP1SMN1; SMN2 | |
| SCHEMBL248151 | 0.92 | KEAP1 (0.56) | SIGMAR1PAOXALOX15KEAP1SMN1; SMN2 | |
| SCHEMBL14854583 | 0.91 | CHKA (0.47) | SIGMAR1PAOXALOX15KEAP1SMN1; SMN2 | |
| SCHEMBL856567 | 0.91 | CHKA (0.47) | SIGMAR1PAOXALOX15KEAP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0614664-B2 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | EP | claimed |
| EP-0614664-B1 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-09-16 | — | — | EP | claimed |
| US-5519024-A | CELL ADHESION INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-05-21 | — | — | US | claimed |
| EP-0375451-A2 | Compounds having a renin-inhibiting activity | BEECHAM GROUP PLC (GB) | 1990-06-27 | — | — | EP | claimed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4731606-A1 | IONIZABLE THIOLIPIDS AND USES THEREOF | BioNTech SE (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-12576040-B2 | Ionizable lipids and methods of manufacture and use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250367131-A1 | IONIZABLE LIPIDS AND METHODS OF MANUFACTURE AND USE THEREOF | George Mason Research Foundation, Inc. | 2025-12-04 | — | — | US | disclosed |
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025027089-A1 | IONIZABLE THIOLIPIDS AND USES THEREOF | BioNTech SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| CN-118652225-A | Phosphorus-free degradable CaSO (CaSOx resistance)4Small molecular scale inhibitor as well as preparation method and application thereof | 石家庄铁道大学 | 2024-09-17 | — | — | CN | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| WO-1996034867-A1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-11-07 | — | — | WO | disclosed |
| WO-1996033978-A1 | QUINAZOLINE DERIVATIVE | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
| WO-1996015128-A2 | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-05-23 | — | — | WO | disclosed |
| US-5519024-A | CELL ADHESION INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-05-21 | — | — | US | disclosed |
| WO-1991010664-A1 | PYRIDAZINO[4,5-b]INDOLIZINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-07-25 | — | — | WO | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
| US-4985560-A | Pyridazino(4,5-b)indolizines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-01-15 | — | — | US | disclosed |
| EP-0375451-A2 | Compounds having a renin-inhibiting activity | BEECHAM GROUP PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576040-B2 | Ionizable lipids and methods of manufacture and use thereof | NPC1L1, NSUN3, CETP | SIGMAR1 2802/4885PAOX 907/4885ALOX15 349/4885 |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | SIGMAR1 126/4885PAOX 2307/4885ALOX15 4670/4885 |
| US-20250367131-A1 | IONIZABLE LIPIDS AND METHODS OF MANUFACTURE AND USE THEREOF | NPC1L1, PLA2G4A, PLA2G2A | SIGMAR1 4458/4885PAOX 535/4885ALOX15 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.